<DOC>
	<DOCNO>NCT00214734</DOCNO>
	<brief_summary>The primary objective post-authorization safety surveillance measure incidence adverse event least possibly related ADVATE use , subject receive ADVATE routine clinical practice .</brief_summary>
	<brief_title>ADVATE Post Authorization Safety Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Subject moderate severe hemophilia A ( baseline FVIII le equal 5 % ) Subject currently measurable FVIII inhibitor titer great equal 1 BU ( Bethesda Nijmegen method ) Subject prescribe ADVATE treat physician Subject may age Subject parent/legally authorize representative provide write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>